Navigation Links
Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Date:12/5/2012

JERSEY CITY, N.J., Dec. 5, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 23rd Annual Oppenheimer Healthcare Conference on Wednesday, December 12, 2012 at 2:45 PM Eastern Time in New York and provide a business overview and update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of the presentation will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.  The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications
Jason I. Spark, Senior Vice President
(619) 849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... and HAMBURG, Germany , February 22, 2017 ... precision oncology headquartered in Hamburg, Germany and ... research institution, announced today a collaboration to support the first Indian ... research. ... Indivumed signed an agreement with an initial three-year term. The collaboration ...
(Date:2/22/2017)... , Feb. 22, 2017  Soligenix, Inc. (Nasdaq: ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today that ... granted a European patent for the treatment of ... methods of treatment of skin conditions, complements the ...
(Date:2/21/2017)... Feb. 21, 2017 Mass Spectrometer Market: ... http://www.reportlinker.com/p04711309-summary/view-report.html This report on mass ... future prospects of the market globally. The stakeholders ... in the manufacture and commercialization of various mass ... entrants planning to enter this market. This report ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, the leading ... Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” http://www.beckersspine.com/spine-leaders/item/35348- ... in Michigan performing minimally invasive back surgery that often results in less post-operative ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of ... report that family members or friends have also commented about their poor hearing. ... wear hearing aids. One reason, suggested by 89 percent of American respondents, is ...
(Date:2/22/2017)... ... ... Social media marketing is transitioning from a singular person activity to a collaborative ... this insight and more in its latest episode of its Brains Over Brawn podcast. ... social media strategist and partner of the digital firm Med|Ed Digital Jessica Columbo. Jessica ...
(Date:2/22/2017)... ... February 22, 2017 , ... In ... advocates stress that the patient context (age, illness and life choices) should be ... mitigate their occurrence. In addition, all too often, studies regarding health ...
(Date:2/21/2017)... Australia (PRWEB) , ... February 22, 2017 , ... Author ... it is valuable for every household and family to know all about it for ... publishing world with the release of “ Detox, Digestive and Wellness Solutions ” (published ...
Breaking Medicine News(10 mins):